Your browser doesn't support javascript.
loading
Autoimmune and auto-inflammatory adverse events after COVID-19 vaccination in the United States.
Kim, Seong-Jang; Rhee, Taeho Greg; Shim, Sung Ryul.
Afiliação
  • Kim SJ; Department of Nuclear Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea; Department of Nuclear Medicine, College of Medicine, Pusan National University, Yangsan, Republic of Korea; BioMedical Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
  • Rhee TG; Department of Psychiatry, School of Medicine, Yale University, New Haven, CT, USA; VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, CT, USA; Department of Public Health Sciences, School of Medicine, University of Connecticut, Farmington, CT, USA.
  • Shim SR; Department of Biomedical Informatics, College of Medicine, Konyang University, 158 Gwanjeodong-ro, Seo-gu, Daejeon 35365, Republic of Korea; Konyang Medical data Research group-KYMERA, Konyang University Hospital, Daejeon, Republic of Korea. Electronic address: sungryul.shim@gmail.com.
Clin Immunol ; 259: 109882, 2024 02.
Article em En | MEDLINE | ID: mdl-38158168
ABSTRACT
We identified 3620 autoimmune-related adverse events among 223.2 million US residents using Vaccine Adverse Events Reporting System and the COVID-19 Data Tracker. This study is the first to quantify the cumulative incidence of autoimmune and auto-inflammatory adverse events after COVID-19 vaccination. We reported autoimmune and auto-inflammatory adverse events across 6 major classes of medical conditions and stratified by age, sex, and manufacturer.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / COVID-19 Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article